The potential of contralateral non-sentinel groin node metastasis in women with early primary vulvar cancer following unilateral sentinel node metastasis: a single center evaluation in University Hospital of Düsseldorf

Andreas Suhartoyo Winarno (dr.andreas.winarno@gmail.com)
Universitatsklinikum Dusseldorf
https://orcid.org/0000-0002-4104-4427

Anne Mondal
Universitatsklinikum Dusseldorf

Franca Christina Martignoni
Universitatsklinikum Dusseldorf

Tanja Natascha Fehm
Universitatsklinikum Dusseldorf

Monika Hampl
Universitatsklinikum Dusseldorf

Research article

Keywords: Vulvar cancer, sentinel lymph node biopsy, non-sentinel lymph node, inguinofemoral lymphadenectomy, ipsilateral / contralateral lymph node metastasis

DOI: https://doi.org/10.21203/rs.3.rs-50733/v2

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: Since the introduction of sentinel node biopsy (SLNB) in unifocal vulvar cancer (diameter of < 4cm) and unsuspicious groin lymph nodes, the morbidity rate of patients has significantly decreased globally. In contrast to SLNB, bilateral inguinofemoral lymphadenectomy (IFL) has been associated with increased risk of common morbidities. Current guidelines (NCCN, ESGO, RCOG, and German) recommend that in cases of unilaterally positive sentinel lymph node (SLN), bilateral IFL should be performed. However, two recent publications by Woelber et al. and Nica et al. contradict the current guideline, since a significant rate of positive non sentinel lymph nodes in IFL contralaterally was not observed (Woelber et al. 0% (p=0/28) and Nica et al. 5.3% (p=1/19)).

Methods: A retrospective single-center analysis conducted in the University Hospital of Dusseldorf, evaluating vulvar cancer patients treated with SLNB from 2002 to 2018.

Results, discussion and conclusion: Current guideline for bilateral IFL should remain as the standard management as 22.2% of women (n=4/18) were found to have contralateral IFL groin metastasis after an initial diagnosis of unilateral SLN metastasis. The depth of tumor infiltrating cells correlated significantly and positively with the rate of incidence of groin metastasis (p=0.0038). Therefore, this depth may be taken into account as an indication for bilateral IFL.

Synopsis

Current guideline for bilateral inguinofemoral lymphadenectomy (IFL) should remain as the standard management of primary early vulvar cancer because 22.2% women in this study had contralateral IFL groin metastasis after unilateral sentinel lymph node biopsy (SLNB) metastasis initially. The depth of tumor infiltrating cells was correlated significantly and positively with the incidence rate of groin metastasis. Therefore, it is an indication for bilateral IFL. Moreover, any vulvar lesion in pregnancy, gynecologist should not hesitate to perform punch biopsy, along with facultative SLNB. Surgical resection in case of proven malignancy showed a comparable good outcome to non-pregnant women.

Data sharing is allowed as DOI for data.

Background

Vulvar cancer (VC) is the fourth most common form of gynecological cancers. In 2016, 4.5 in 100,000 women/year, with a 5-year survival rate of 71% and mortality rate of 0.9 in 100,000 was reported in Germany, according to Robert Koch Institute’s data (RKI). A similar incidence is observed in the United States of America (USA) (surveillance, epidemiology, and end results program (SEER)) with an occurrence rate of 2.5 in 100,000 women/year, with a 5-year survival rate of 71% and mortality rate of 0.5 in 100,000 women/year.
In cases with locally confined histologically proven invasive (> 1mm tumor depth) VC, complete resection of the tumor area ‘residual zero’ is the gold standard of current treatment. Complete (radical) dissection of inguinofemoral LN or lymphadenectomy (IFL), was formerly the standard of groin staging. Following the publication of GRoningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V) in 2008 which showed that SLNB is safe in early vulvar cancer, the treatment modality was replaced in many countries with sentinel lymph node (SLN) biopsy (B) with radioactive tracer technetium 99m nanocolloid (Tc-99m) and/or blue dye. The advantage of SLNB is the reduction in both morbidity (lymph cyst, lymphedema of leg, cellulitis or erysipelas) and mortality rates (septic shock due to wound infection and thromboembolism), shorter hospital stay and cost benefit implications. However, SLN has limitations including unifocallity of the tumor, tumor size less than 4 cm, clinically unsuspicious LN in the groin and the need to inject radiocolloids before operating. Complex logistic and the expense of radioisotopes are also problematic. Moreover, blue dye as an alternative also has limitations such as inability to penetrate skin and fatty tissue and blue staining of the operation field.

GROINSS-V also reported that the recurrence rate of SLNB was low with 2.3% (95% CI, 0.6% to 5%) after a median follow up of 35 months in unifocal VC, with excellent 3-year survival rate 97% (95% CI, 91% to 99%) and minimal morbidity SLNB compared with IFL. Wound break down was 11.7% vs 34% in SLNB; cellulitis 4.5% vs 21.3%; erysipelas 0.4% vs 16.2%; and lymphedema of the legs 1.9% vs 25.2%. The false negative rate of SLNB was about 8.3%. The latest European expert panel recommends that SLN detection could be improved by use of indocyanine green (ICG) and additional application of SPECT/CT imaging can reduce the false negative results. It is also worth noting that the recurrence rate of metastasis was 2.7% with SLNB and 1.4% with IFL. The survival rate, in the case of isolated groin lesion recurrence, was reported worser in women with primary local VC > 4cm than < 4cm in initial negative SLNs with 9% versus 5% respectively. AGO-Care-1 cohort study showed that 60% of women with VC bigger than 4 cm had at least 1 metastatic LN. Therefore, the current recommendation is to use SLNB only for tumors less than 4 cm of diameter. Many studies show that the amount of groin LN metastasis is a significant negative predictor for survival. Recurrences of metastatic LN in the groin are associated with high mortality rates.

Moreover, the procedure itself should be performed only in dedicated hospitals, by surgeons with specialty expertise and adequate number of procedures-per year.

In the case of SLNB with positive unilateral metastasis, current German guidelines recommend bilateral IFL as standard treatment. European Society of Gynaecological Oncology (ESGO), Royal College of Obstetricians and Gynecologists (RCOG), and National Comprehensive Cancer Network (NCCN) are in accordance with the German guideline.

This retrospective single center study aims to evaluate whether the current guideline should remain as standard care or whether there is evidence to recommend the omission of a complete IFL resection of the contralateral groin in the case of positive unilateral SLN only.
Methods

Patients

All patients were diagnosed with primary vulvar squamous cell carcinoma at the Obstetrics (O) and Gynecology (G) clinic in the University Hospital of Düsseldorf between 2002 and 2018 (Diagram 1). The Ethics committee of the medical board of Heinrich Heine University approved the retrospective investigation of patients’ medical records (reference number 2019-491). Out of the 420 women who were evaluated, 369 women with negative metastasis of SLNB were ruled out. Of the remaining 51 women, 30 had unilateral SLNB metastasis and 21 had bilateral SLNB metastasis. Inclusion criteria for SLNB procedures were Stage IB, II VC and tumor size less than 6cm without suspicious groin LN clinically. Exclusion criteria were multifocality, tumor size above 4 cm with highly suspicious groin LN, and distant metastasis at initial diagnosis or consent refusal of the patients due to the potential increased risks of groin recurrence. In the final analysis, we focused on women with positive SLN unilaterally.

Removal of primary tumor and identification of sentinel node

Vulvar tumor was resected locally with ≥3mm tumor free margin or partial/total vulvectomy. The surgical procedure was performed by one experienced vulvar surgeon with rare exception. If in the final histology report, tumor free margin was reported to be less than 3 mm, an additional resection was performed separately. Regional flaps for wound closure were used when indicated. In pregnancy, primary tumor was resected immediately in any gestational age after punch biopsy confirmed malignancy.

One day before surgery, all patients underwent peritumoral intradermal injection of Tc-99m at three, six, nine and twelve o’clock using a 27-gauge needle. An hour following the injection, a planar lymphoscintigraphy was performed with anterior and lateral static view. This procedure followed the GROINSS-V protocol adapted by German guideline. However, a short protocol with dose reduction was chosen for pregnant women. SLNB procedure was performed after 14 weeks of pregnancy (WP). The administration of Tc-99m was lower than 100MBq. An abdominal shield was used to protect the fetus from radiation in performing planar lymphoscintigraphy. These procedures were done two hours before the SLNB operation.

On the day of surgery, a handheld gamma probe (Neoprobe GDS, BT Devicor Mammotomo, Cincinnati, OH, USA) was used to identify marked groin nodes bilaterally. In the case of SLN metastasis in final histology, IFL was further performed separately with patient consent. Pelvic node dissection was indicated in accordance with German guideline: more than two metastatic nodes or one metastatic node ≥5mm or extracapsular spread.

Histopathology

Pathological examination was performed in the Department of Histopathology at University Hospital of Düsseldorf. A standard protocol has been established for all sentinel node procedures which included
frozen sections of LNs (not in all cases performed), hematoxylin and eosin staining, subsequent ultrastaging and immunohistochemistry with three sections per 5mm, similar to the GROINSS-V study protocol. 4, 6, 26-29

**Classification**

VC was classified into tumor (T), nodal (N), metastasis (M), grading (G), perineural (Pn), lymphovascular space (L) or blood vessel (V) infiltration and resection status (R) histologically. The International Federation of Gynecology and Obstetrics (FIGO) system was used for clinical staging.

**Statistics**

All groups were analyzed using one-way ANOVA to determine their statistical significance. P-values of <0.05 was considered to be statistically significant. One-way ANOVA analysis was done with Microsoft Excel professional plus 2016 (Table 1). Graph prism 8.3 was used to analyze the overall survival (OS) using Kaplan Meier curve (Figure 1). The minimum follow-up period of the patients was 12 months after initial diagnosis, also their initial diagnosis of VC was at about 6-8 years ago. Due to the retrospective nature of the study, 8 of 18 women were lost in follow up, due to changes in their home address, gynecologist and/or phone number. Attempts to contact all these cases were without success. In addition, some patients were lost in subsequent follow-up because they were examined by their local gynecologists or at the nearest hospitals.
Our data were collected from 420 women with early primary VC and bilateral SLNB from 2002 to 2018. Fifty-one women (12.1%) had either unilateral SLN metastasis (n=30; 58.8%) or bilateral SLN metastasis (n=21; 41.2%). Those with unilateral SLN metastasis (n=30) had a median age of 51.5 years old (SD ± 14.4; max 82; min 27) and were further divided into two groups (Diagram 1):

| SLNB                      | Group 1 (n=12) | Group 2A&B (n=14) | Group 2C (n=4) | p-value* |
|---------------------------|----------------|-------------------|----------------|----------|
| Age (years)               |                |                   |                |          |
| Median (range)            | 50 (28-79)     | 52.5 (27-82)      | 55 (51-67)     | 0.793    |
| Primary vulvar tumor      |                |                   |                |          |
| location                  |                |                   |                |          |
| Midline                   | 9 (75%)        | 11 (78.6%)        | 4 (100%)       | 0.553    |
| Lateralized               | 3 (25%)        | 3 (21.4%)         | 0              |          |
| Diameter (mm)             |                |                   |                | 0.7645   |
| Median (range)            | 15.5 (6.0-54.0)| 19.5 (9.0-60.0)   | 22.5 (16.0-35.0)|          |
| Diameter categories       |                |                   |                | 0.245    |
| <20mm                     | 7 (58.3%)      | 7 (50%)           | 1 (25%)        |          |
| ≥20mm but <40mm           | 3 (25%)        | 5 (35.7%)         | 3 (75%)        |          |
| ≥40mm                     | 2 (16.7%)      | 2 (14.3%)         | 0              |          |
| Depth (mm)                |                |                   |                | 0.0038   |
| Median (range)            | 3.0 (1.8-6.0)  | 6.0 (2.0-15.0)    | 8.5 (5.0-23.0) |          |
| Grade                     |                |                   |                | 0.410    |
| 1                         | -              | -                 | -              |          |
| 2                         | 10 (83.3%)     | 11 (78.6%)        | 2 (50%)        |          |
| 3                         | 2 (16.7%)      | 3 (21.4%)         | 2 (50%)        |          |
| Radiotherapy              | 4 (33.3%)      | 6 (42.9%)         | 3 (75%)        |          |
| Chemotherapy              | 0              | 2 (14.3%)         | 2 (50%)        |          |
| Local recurrence          | 1 (8.5%)       | 1 (7.1%)          | 1 (25%)        |          |
| Groin recurrence          | 1 (8.3%)       | 0                 | 0              |          |
| (fat tissue)              |                |                   |                |          |
| Distant Metastases        | 1 (8.3%)       | 0                 | 1 (25%)        |          |

Table 1: Patient, disease and treatment characteristics. A p-value of less than 0.05 is considered to be statistically significant.

Results

Our data were collected from 420 women with early primary VC and bilateral SLNB from 2002 to 2018. Fifty-one women (12.1%) had either unilateral SLN metastasis (n=30; 58.8%) or bilateral SLN metastasis (n=21; 41.2%). Those with unilateral SLN metastasis (n=30) had a median age of 51.5 years old (SD ± 14.4; max 82; min 27) and were further divided into two groups (Diagram 1):
**Group 1.** Twelve women (n=12/30; 40%) had **ipsilateral IFL only**, in accordance with the patient’s desire to avoid the increased morbidity of bilateral groin surgery and/or old age. Only one woman was diagnosed having an additional positive metastatic LN in IFL (1/12=8.3% (group 1B) and 11 women (11/12 = 91.7%) (group 1A) had no further metastatic LNs in IFL.

- One woman (n=1/11; 9.1%) in group 1A suffered from local recurrence 6 months after initial diagnosis and she survived at 60 months’ follow-up.
- One woman (n=1/11; 9.1%) in group 1A experienced VC recurrence in the fat tissue of the groin 18 months after initial diagnosis of ipsilateral IFL without further metastatic LNs. She had an initial diagnosis with 5.4cm tumor diameter of focal VC. She received re-surgery and radiotherapy and still survived at 60 months’ follow-up examination.
- One woman (n=1/11; 9.1%) in group 1A had 4.7cm tumor diameter at initial diagnosis and a 5mm left-sided SLN metastasis with extracapsular spread and due to their own decision only IFL on the ipsilateral side including left sided pelvic LN dissection was performed revealing no further metastatic LNs in IFL or iliac nodes. Therefore, radiotherapy was suggested for vulvar region (R1 resection, G3 tumor) and bilateral groin. Unfortunately, she was diagnosed with metastases in both lungs, liver and bone 15 months later. Her bronchial biopsy result was negative for p16 expression in tumor cells, whereas the VC has been positive for p16 expression suggesting a HPV induced vulvar cancer. Histologically, both tumors were squamous cancer cells. Therefore, she was suspected to have primary lung cancer in addition to her vulvar cancer. She received palliative radio-chemotherapy.
- There was only one woman (n=1/12; 3.3%) with subsequent metastatic LN in ipsi-unilateral IFL. She had received radiotherapy to her right groin. She survived 24 months after initial diagnosis and then was lost in subsequent follow-up.

**Group 2.** Eighteen women (n=18/30; 60%) who received complete bilateral IFL were further divided into three subgroups:

A: Thirteen women (n=13/18; 72.2%) had negative IFL results in both groins.

- Interestingly, a 30-year old woman from subgroup 2A was diagnosed with VC in her second pregnancy. Her clinical complaints were persistent itchiness, pain and ulceration of vulva. A punch biopsy showed keratinized squamous cell cancer. Therefore, removal of the vulvar ulcerative lesion was done at 7th weeks of pregnancy (WP) and SLNB at 19th WP revealing a unilateral metastatic SLN. She received bilateral IFL at 20th. She subsequently had an uneventful pregnancy and delivered her baby via caesarean section at term. Her most recent examination, 60 months after initial diagnosis, at our outpatient clinic showed no sign of recurrence.
- Another 36-year old woman had similar complaints at 23rd WP and her punch biopsy result showed low-grade chronic inflammation, reactive squamous cell hyperplasia and hyperkeratosis. Fourteen months later, while still breastfeeding, VC was diagnosed with a non-keratinized squamous cell type
of carcinoma located at the right labia minora with extension close to the clitoris. Standard surgery revealed a left-sided SLN metastasis of 3mm with extracapsular tumor cell spread. Consecutive bilateral IFL did not find any further metastatic lymph nodes. As a result, she received radiotherapy on her left groin and follow-up examination at 60 months after initial diagnosis showed no sign of recurrence.

- A woman had 5.7 cm focal tumor diameter of initial diagnosis VC. The follow up was uneventful.

B: One woman (n=1/18; 5.8%) had further metastatic lymph nodes in the ipsilateral IFL.

C: Four women (n=4/18; 22.2%) had contralateral groin metastatic LN in IFL following unilateral SLN metastasis initially (Table 2).

- One woman (n=1/4; 25%) from Group 2C developed mons pubis malignant squamous cell tumor. The focal tumor was at anterior fourchett between clitoris and urethra. 18 months later, radio-chemotherapy after surgical in toto removal of this tumor occurred.
All of the 30 women (n=30/51; 58.8%) with positive unilateral SLNB had pT1b VC, except for one with pT2. A majority of the women with positive unilateral SLNB (n=24/30; 80%) suffered from anterior midline lesions between clitoris and urethra. The median size of tumors was 1.9 cm (SD ± 1.4 cm) and the median depth of tumor cell infiltration was 5 mm (SD ± 4.4mm). Only one woman (n=1/30; 3.3%) had posterior midline vulvar lesion. Five women (n=5/30; 16.7%) had lateralized lesions. In contrast, all women with contralateral groin metastatic lymph nodes in IFL (subgroup 2C) had anterior midline lesions.
In this study, we would like to highlight the side effects and complications post-surgery from Groups 1 and 2. Thirteen women (n=13/30; 43.3%) suffered edema of the foot and required lymphatic drainage therapy. Nine women (n=9/30; 30%) developed lymph cysts and five women (n=5/30; 16.7%) had erysipelas and required antibiotic therapy. The comparison from each group regarding the complications postoperatively is shown in Table 3. Three women (n=3/30; 10%), one woman from each Group 1, 2A and 2C, developed local recurrence of VC.

OS analysis was performed for all 30 women with unilateral SLN metastasis. The five years’ survival rates were 90.9% in Group 1, 80% in Group 2A/B and 75% for the four women in Group 2C.

|                          | Ipsi-Unilateral IFL | Bilateral IFL | Bilateral IFL |
|--------------------------|---------------------|---------------|---------------|
|                          | Group 1             | Group 2 A&B   | Group 2C      |
| Edema of legs            | 25% (n=3/12)        | 42.8% (n=6/14)| 75% (n=3/4)  |
| Lymph cyst               | 25% (n=3/12)        | 28.6% (n=4/14)| 50% (n=2/4)  |
| Erysipelas               | 25% (n=3/12)        | 14.3% (n=2/14)| 0% (n=0/4)   |

Table 3: the postoperative complication from each group.

Discussion

Since the introduction of GROINSS-V study in 2008, SLNB of the groin has played a central role in the management of VC. Firstly, SLNB has reduced morbidity and mortality rates, whereas radical IFL has significant side effects.\(^6\) Secondly, the necessity for IFL remains controversial in the case of positive unilateral SLNB, as to whether it should be done ipsilaterally or bilaterally.\(^1\)\(^-\)\(^8\) This is due to the fact that when recurrent groin metastasis occurs, the survival rates of these patients decrease significantly.\(^9\)\(^-\)\(^25\),\(^30\)\(^-\)\(^33\) The long-term follow-up of GROINSS-V showed that the 10-year disease-specific survival rates in the cases of local recurrence was reduced from 90.4% to 68.7% and in patients with positive SLNB from 77.7% to 44.6%.\(^10\)

A German study of Woelber et al.\(^7\), showed in none of the cases of primary VC with positive unilateral SLN contralateral positive LN in consecutive bilateral IFL (0/28 cases, 0%). A Canadian study (Nica et al.)\(^8\) reported that only 1 of 19 patients (5.3%) had a contralateral metastatic LN in IFL following unilateral SLN metastasis. But, two of their patients with positive unilateral SLNB had a groin recurrence (one located unilaterally and the other contralaterally) several months following negative IFL.\(^8\) Therefore, they suggest it is reasonable to omit contralateral IFL in patients with unilateral SLN metastasis. Both studies are in contrast to our findings with 4/18 (22.2%) women with unilateral positive SLN diagnosed with contralateral positive LN in IFL. The reason for this discrepancy may be the fact, that in our study,
the tumors of these four women were all located in the midline. Unfortunately, Woelber et al. and Nica et al. did not specify the location of the tumors, if they were midline or lateral.\textsuperscript{7,8,12}

Over the past decade, there has been an increasing trend for midline VC\textsuperscript{34-37}. In our hospital, the overall percentage of VC located in the anterior fourchette area is approximately 60%. Four cases with contralateral IFL metastasis in our study had originated from midline lesions. Therefore, our data suggests if the patient has unilateral SLN metastasis, clinicians should offer radical bilateral IFL in case of midline tumors. This is the current recommendation in German guideline.\textsuperscript{4} Our retrospective single-center study results with a rate of 22\% of contralateral positive LN after unilateral positive SLN confirms that current guidelines are appropriate and should \textbf{not} be amended or changed, because our results suggest, that the risk of groin recurrences will be significant if the contralateral groin resection is omitted, also taking into account that none of the women with ipsilateral IFL only (12/30 women, own wish) developed a groin recurrence in the follow up period.

According to our results, the depth of tumor cells infiltration is also a significant factor in the prediction of contralateral metastasis (p=0.0038). The median depth of tumor infiltration was 3mm in group 1, 6mm in group 2A/B and 8.5mm in group 2C. Nonetheless, the diameter of the tumor is statistically insignificant (p = 0.764) in our evaluation. Our findings related to depth of tumor infiltration is in concordance to the current statement in German guideline with the possibility of groin metastasis depending on depth of tumor infiltration: $\leq$1mm; 0\%; 1.1-2mm, 7.6\%; 2.1-3mm, 8.3\%; 3.1-5mm, 26.7\% and 5mm, 34.2\%, respectively.\textsuperscript{4} The depth of tumor has also been proposed to be taken into consideration for the decision on the extent of surgery and further management of VC.\textsuperscript{25,38} Future research should aim for bigger sample size and evaluate the correlation between the depth of tumor cells infiltration and the risk of contralateral groin metastasis. In addition, perineural invasion (PVI) has been reported to be an unfavorable prognostic factor for the outcome of patients indicating a more aggressive behavior of VC. Therefore, adjuvant treatment has been suggested in those women.\textsuperscript{39} However, in our study, only 3 of 30 women with unilateral positive SLN had PVI in the primary tumor. One woman was from group 2A (negative bilateral IFL) and 2 women belonged to group 1A (negative unilateral IFL). The follow up of all these women was uneventful up to 60 months suggesting that PVI is not an unfavorable prognostic factor in our cohort.

In the case of lateralized lesion, the removal of contralateral LNs in case of unilateral positive SLNB should be discussed with the patients in regards to its benefits, risks and possible side effects. According to our results, it may perhaps be omitted but due to the low number of lateralized lesions in our study (20\%), future prospective evaluation of lateralized lesions in VC is warranted. The few cases with lateralized lesions in our cohort of women with unilateral positive SLN (6/30 women) is the limiting factor to draw clear conclusions regarding the impact of contralateral IFL. In comparison, Woelber et al. and Nica et al. did not specify the location of the tumors in their study, as to whether they were midline or lateralized.\textsuperscript{7,8,12} We suspect that it might be possible that the majority of their study subjects had
lateralized tumors. This might explain why their radical bilateral IFL results had not shown any contralateral non-sentinel metastasis in contrast to our findings.

Perhaps there will be an alternative treatment option to avoid morbidity of IFL: According to a recently published study GROINSS V-II, radiotherapy could replace IFL if the tumor diameter is < 4cm and SLNB metastasis is < 2mm. However, in the case of sentinel node metastasis of > 2mm, radiotherapy is not a safe alternative of IFL.\textsuperscript{33} In addition, there is currently an ongoing nationwide study of VC in Sweden with inclusion criteria primary tumor \( \geq \) 4cm, primary multifocal tumors or local recurrences, being an exclusion criterion so far. The results will be expected at the end of 2021 and this could change the current clinical approach of SLNB in primary VC.\textsuperscript{40}

VC may also be diagnosed in pregnancy, in our center 5 women were diagnosed and treated in pregnancy within the last 15 years. We performed SLNB in collaboration with our department of nuclear medicine also in pregnant women after extensive counseling regarding the advantages and risks of the technique and written consent of the women. According to the current recommendations,\textsuperscript{41-43} this procedure should be done after the end of the 14th week of pregnancy (first trimester) to be safe for the fetus. In pregnancy, a lower dose of radioactive Tc-99m should be injected using a short-treatment protocol (SLNB can be done two hours following injection with lowest possible dose). The half-life of technetium 99m is six hours. Prompt nodal removal can reduce the chance of systemic exposure, even though fetal exposure is considered low when technetium is injected locally in the peritumoral region.\textsuperscript{41-43} Moreover, diagnosis of VC in pregnancy is often delayed. A systematic review showed that the time interval from the first medical visit until first diagnosis of VC was more than eight weeks (62.5%). The first reason is low suspicion due to the rare occurrence of VC in younger-aged women (70%), second is noncompliance of patients (30%), and third is potential risk of vulvar biopsy resulting in feto-maternal complications during pregnancy.\textsuperscript{43} In comparison to all gynecological cancers in pregnancy, VC is in fact considered to have the least possible complications in patients who undergo biopsy and/or operation.\textsuperscript{41-43}

Our data showed comparable morbidity of IFL with the reported data in the literature in respect of infection, lymph cysts, and lymphedema of the legs being 21.3 - 35.4%, 11 - 40% and 14 - 48.8%, respectively.\textsuperscript{44}

Although the overall survival (OS) of the patients in group 1, group 2 A/B and group 2C with contralateral positive LNs in IFL after negative SLNB is statistically not significant (p=0.623, log rank test with Mantel Cox) (p=0.517, Gehan-Breslow-Wilcoxon test, Figure 1), there is a visible trend towards decreased survival in the women of group 2C with contralateral positive lymph nodes in IFL (Figure 1). Interestingly and also unexpectedly, none of the women of group 1 who received only unilateral IFL due to unilateral positive sentinel lymph nodes developed groin recurrence in the observation time of 60 months. Neither in the contralateral groin nor unilaterally. No comparable survival rates exist in the literature since in the study of Woelber et al.\textsuperscript{7} and Nica et al.\textsuperscript{8} patients with negative SLNB were compared to women with metastatic groin LNs.
The limitations of this study are retrospective nature of data analysis, loss of some patients in follow-up examinations beyond 12 months following initial VC diagnosis in our clinic because of change of address/phone number or switch to a new local gynecologist. Some patients were initially diagnosed in 2018 resulting in short follow up time. A further weakness is the small sample size of patients with lateralized vulvar tumor location.

**Conclusion**

From our current findings, we confirm that radical bilateral IFL should be offered in treatment management of primary VC with anterior midline lesion and unilateral SLN metastasis. This is based on the findings that 4/18 (22.2%) women with unilateral positive SLN were further diagnosed with contralateral positive nodes using IFL. In our study, the tumors of these four women were located in the midline. However, the need for radical bilateral IFL in cases of lateralized tumor with positive ipsilateral SLNB should be further evaluated. Furthermore, the depth of tumor infiltrating cells correlated significantly and positively with the incidence rate of groin metastasis (p=0.0038). According to our experience, in case of pregnancy, a punch biopsy is necessary in the management of suspicious vulvar lesion, along with facultative SLNB and surgical resection methods in case of proven malignancy with comparable good outcome to non-pregnant women. The management of VC and SLNB should be performed in a high volume center with an experienced team in marking SLN and performing the adequate surgical procedure. Well conducted counseling of the patients outlining advantages but also potential oncological risks of this technique especially concerning rate of groin recurrence is critical.

**Abbreviations**

| Abbreviation | Description |
|--------------|-------------|
| B            | Biopsy      |
| ESGO         | European Society of Gynecological Oncology |
| FIGO         | International Federation of Gynecology and Obstetrics |
| GOG 173      | Gynecologic Oncology Group 173 |
| GROINSS-V    | GROningen INternational Study on Sentinel nodes in Vulvar cancer |
| HIV          | Human Immunodeficiency Virus |
| HPV          | Human Papilloma Virus |
| IFL          | Inguino-Femorale Lymphadenectomy / complete radical groin dissection |
| G            | Gynecology |
| LN           | Lymph Node |
Declarations

Ethics approval and consent to participate

The Ethics committee at the medical board of Heinrich Heine University has approved the retrospective investigation of patients’ medical records (reference number 2019-491). All patients had approved their clinical history for the purpose of research and publication.

Consent for publication

This publication follows the ethical guideline in the declaration of Helsinki.

Availability of data and material

All patients were diagnosed with primary vulvar squamous cell carcinoma at the department of Obstetrics (O) and Gynecology (G), University Hospital of Düsseldorf (UHD) between 2002 and 2018.

Competing interest

The authors declare that there is no conflict of interest regarding the publication of this article.
Funding

None of the authors received any funding for this study. This study is purely for scientific use and aimed to provide suggestions for current clinical guidelines and future research.

Authors’ contributions

ASW: validation, formal analysis, investigation, conceptualization, writing – original draft preparation, writing and editing

MH: conceptualization, draft, review, resources and supervision

AM: review

FCM: review

TNF: review

All authors have read and approved the manuscript

Acknowledgements

Thanks to Prof. Jaye PF Chin-Dusting (National Health and Medical Research Council, Monash University, Melbourne, Australia) and Rosemary Gunawan B.Biomed(Hons) in correcting the manuscript

References

1. Christ M, Folkerts J, Hansmann J, et al. Krebs in Deutschland für 2015/2016 (Cancer in Germany for 2015/2016). Robert Koch-Institut (Zentrum für Krebsregisterdaten), Kapitel 3, 2019 Berlin, Germany

2. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2016, National Cancer Institute 2019.

3. Luesley DM, Tristram A, Ganesan R. Guideline for the diagnosis and management of vulval carcinoma. Royal College of Obstetricians and Gynecologists (RCOG) 2014: https://www.rcog.org.uk/globalassets/documents/guidelines/vulvalcancerguideline.pdf

4. Hampel M, Schnürch HG, Ackermann S, et al. Diagnosis, Therapy and Follow-up of Vaginal Cancer and Its Precursors. Guideline of the DGGG and the DKG (S2k-Level, AWMF Registry No. 032/042, October 2018). Geburtshilfe und Frauenheilkunde 2019; 79 (10): 1060-1078.

5. Alkatout I, Schubert M, Garbrecht N, et al. Vulvar cancer: epidemiology, clinical presentation and management options. International Journal of Women’s Health 2015; 7: 305-313.

6. Van der Zee AGJ, Oonk MHM, De Hullu JA, et al. Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. Journal of Clinical Oncology 2008; 26(6): 884-889.
7. Woelber L, Eulenburg C, Grimm D, et al. The risk of contralateral non-sentinel metastasis in patients with primary vulvar cancer and unilaterally positive sentinel node (Original article). Annals of Surgical Oncology 2016; 23: 2508-2514.

8. Nica A, Covens A, Vicus D, et al. Sentinel lymph nodes in vulvar cancer: management dilemmas in patients with positive nodes and larger tumors. Gynecologic Oncology 2019; 152: 94-100.

9. Oonk MHM, Van Hemel BM, Hollema H, et al. Size of sentinel-node metastasis and chances of non-sentinel-node involvement and survival in early stage vulvar cancer: results from GROINSS-V, a multicenter observational study. Lancet Oncology 2010; 11: 646-652.

10. Te Grootenhuis NC, Van der Zee AGJ, Van Doorn HC, et al. Sentinel nodes in vulvar cancer: long-term follow-up of the GROningen International Study on Sentinel nodes in vulvar cancer (GROINSS-V) I. Gynecologic oncology 2016; 140: 8-14.

11. Oonk MHM, Planchamp F, Baldwin P, et al. European Society of Gynecological Oncology Guidelines for the management of patients with vulvar cancer. International Journal of Gynecological cancer 2017; 27: 832-837.

12. Oonk MHM, van der Zee AGJ. The risk of contralateral non-sentinel metastasis in patients with primary vulvar cancer and unilaterally positive sentinel node (Editorial). Annals of Surgical Oncology 2016; 23: 2383-2384.

13. Covens A, Vella ET, Kennedy EB, et al. Sentinel lymph node biopsy in vulvar cancer: systematic review, meta-analysis and guideline recommendations. Journal of Gynecologic Oncology 2015; 137: 351-361.

14. Berek JS, Karam A, Goff B, et al. Vulvar cancer: epidemiology diagnosis, histopathology and treatment of rare histologies. UpToDate 2019; 23(3237): 1-32.

15. Verbeek FPR, Tummers QRJG, Rietbergen DDD, Peters AAW, Schaarfsma BE, van de Velde CJH, Frangioni JV, van Leeuwen FWB, Gaarenstroom KN, Vahrmeijer AL. Sentinel Lymph Node Biopsy in Vulvar Cancer using Combined Radioactive and Fluorescence Guidance. Int J Gynecol Cancer. 2015; 25(6): 1086–1093.

16. Prader S, du Bois A, Harter P, Breit E, Schneider S, Baert T, Heitz F, Traut A, Ehmann S, Pauly N, Heikaus S, Moka D, Ataseven B. Sentinel lymph node mapping with fluorescent and radioactive tracers in vulvar cancer patients. Archives of Gynecology and Obstetrics 2020; 301: 729–736.

17. Levenback CF, Ali S, Coleman RL, et al. Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a gynecologic oncology group study. Journal of Clinical Oncology 2012; 30(31): 3786-3791.

18. Collarino A, Fuoco V, Garganese G, Arias-Bouda LMP, Perotti G, Manca G, Vidal-Sicart S, Giammarile F, de Geus-Oei LF, Scambia G, Giordano A, A Valdes-Olmos R, Maccauro M. Lymphoscintigraphy and sentinel lymph node biopsy in vulvar carcinoma: update from a European expert panel. Eur J Nucl Med Mol Imaging. 2020 May;47(5):1261-1274.

19. Klapdor R, Wölber L, Hanker L, Schmalfeldt B, Canzler U, Fehm TN, Luyten A, Hellriegel M, Kosse J, Heiss C, Hantschmann P, Mallmann P, Tanner B, Pfisterer J, Jückstock J, Hilpert F, de Gregorio N,
Hillemanns P, Fürst ST, Mahner S. Predictive factors for lymph node metastases in vulvar cancer. An analysis of the AGO-CaRE-1 multicenter study. Gynecol Oncol. 2019 Sep;154(3):565-570.

20. S. Mahner, J. Jueckstock, F. Hilpert, P. Neuser, P. Harter, N. de Gregorio, et al., Adjuvant therapy in lymph node-positive vulvar cancer, the AGO-CaRE-1 study, JNCI 107 (3) (2015) (dju426-dju426).

21. L. Woelber, C. Eulenburg, M. Choschzick, A. Kruell, C. Petersen, F. Gieseking, et al. Prognostic role of lymph node metastases in vulvar cancer and implications for adjuvant treatment, Int. J. Gynecol. Cancer 22 (3) (2012) 503–508.

22. R. Klapdor, H. Hertel, P. Soergel, P. Hillemanns, Groin recurrences in node negative vulvar cancer patients after sole sentinel lymph node dissection, Int. J. Gynecol. Cancer 27 (1) (2017) 166–170.

23. Meads C, Sutton AJ, Rosenthal AN, Malysiak S, Kowalska M, Zapalska A, Rogozinska E, Baldwin P, Ganesan R, Borowiack E, Barton P, Roberts T, Khan K, Sunda S. Sentinel lymph node biopsy in vulval cancer: systematic review and meta-analysis. British Journal of Cancer (2014) 110, 2837–2846

24. Van der Zee A, Oonk M, Planchamp F, et al. Vulvar cancer guidelines. European Society of Gynecological Oncology (ESGO): https://www.esgo.org/media/2016/10/ESGO-Vulvar-cancer-Brochure.pdf

25. Koh WJ, Greer BE, Abu-Rustum NR, et al. Vulvar cancer, version 1.2017: clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network 2017; 15(1): 92-120.

26. Nijman TAJ, Schutter EM, Amant F. Sentinel node procedure in vulvar carcinoma during pregnancy. Journal of Gynecologic Oncology Reports 2012; 2: 63-64.

27. Spanheimer PM, Graham MM, Sugg SL, Scott-Conner S, Weigel RJ. Measurement of uterine radiation exposure from lymphoscintigraphy indicates safety of sentinel lymph node biopsy during pregnancy. Ann Surg Oncol 2009; 16: 1143-1147.

28. Schmidt M, Bares R, Brenner W, Buck A, Grünwald F, Kopp J, Krause BJ, Schober O, Sciuk J, Sudbrock F, Wegenmair H. Verfahrensanweisung für die technische Durchführung der nuklearmedizinischen Wächter-Lymphknoten-Diagnostik (S1 Leitlinien). Deutsche Gesellschaft für Nuklearmedizin 2014; AWMF 31-33.

29. Anne Kathrin Höhn, Christine E. Brambs, Ramona Erber, Grit Gesine Ruth Hiller, Doris Mayr, Dietmar Schmidt, Elisa Schmoeckel & Lars-Christian Horn. Leitlinienbasierte Aufarbeitung und Befundung von Lymphonodektomiepräparaten und Sentinel-Lymphknoten gynäkologischer Malignome. Der Pathologe (2020)

30. Meads C, Sutton AJ, Rosenthal AN, et al. Sentinel lymph node biopsy in vulvar cancer: systematic review and meta-analysis. British Journal of Cancer 2014; 110: 2837-2846.

31. Slomovitz BM, Coleman RL, Oonk MHM, et al. Update on sentinel lymph node biopsy for early-stage vulvar cancer (Review article). Journal of Gynecologic Oncology 2015; 138: 472-477.

32. Sykes P, Eva L, Van der Griend R, et al. Pathological process has a crucial role in sentinel node biopsy for vulvar cancer. Journal of Gynecologic Oncology 2019; 153: 292-296.

33. Oonk MHM, Slomovitz B, Baldwin P, et al. Radiotherapy instead of inguinofemoral lymphadenectomy in vulvar cancer patients with a metastatic sentinel node: results of GROINSS-V II. International
34. Hampl M, Deckers-Figiel S, Hampl JA, et al. New aspects of vulvar cancer: changes in localization and age of onset. Journal of Gynecologic Oncology 2008; 109 (3): 340-345
35. Hampl M, Hantschmann P, Michels W, German Multicenter Study Group. Validation of the accuracy of the sentinel lymph node procedure in patients with vulvar cancer: results of a multicenter study in Germany. Journal of Gynecologic Oncology 2008; 111(2): 282-288.
36. Hampl M, Kueppers V, Bender HG. Single large inguinal lymph node metastasis in human papillomavirus-induced early invasive vulvar cancer of the anterior fourchette in two young women. Journal of Gynecologic and Obstetric Investigation 2009; 67(1): 42-45.
37. Reuschenbach M, Roos J, Panayotopoulos D, et al; German Study Group for Colposcopy. Characterization of squamous cell cancer of the vulvar anterior fourchette by human papillomavirus, p16INK4a and p53. Journal of Lower Genital Tract Disease 2013; 17(3): 289-297.
38. Van den Einden LC, Massuger LF, Jonkman JK, et al. An alternative way to measure the depth of invasion of vulvar squamous cell carcinoma in relation to prognosis. Mod Pathol 2015; 28: 295-30
39. Ferrari F, Forte S, Ardighieri L, Bonetti E, Fernando B, Sartori E, Odicino F. Multivariate analysis of prognostic factors in primary squamous cell vulvar cancer: The role of perineural invasion in recurrence and survival. European Journal of Surgical Oncology 2019: 45 (11): 2115-2119
40. Zach D. Sentinel Node Extended in Squamous Cell Vulvar Cancer (SNEX). 2019. ClinicalTrials.gov Identifier: NCT04147780
41. Amant F, Berveiller P, Boere IA, et al. Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting (ESMO Review). Annals of Oncology 2019; 30 (10): 1-12.
42. Palmer JE, Tidy JA. Pregnancy following vulvar squamous cell carcinoma: a report of two cases. Journal of Gynecologic Oncology 2009; 20 (4): 254-256.
43. Matsuo K, Whitman SA, Blake EA, et al. Feto-maternal outcome of pregnancy complicated by vulvar cancer: a systematic review of literature. Eur J Obstet Gynecol Reprod Biol. 2014; 179: 216-223.
44. Wills A, Obermair A. A review of complications associated with the surgical treatment of vulvar cancer. Gynecologic Oncology 2013; 131: 467-479.

Figures
Figure 1

Kaplan Meier curve of patient’s survival rates. OS analysis results show 90.9% for group 1, 80% for group 2AB and 75% for group 2C. Group divisions can be seen in Diagram 1.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Diagram1.pdf